Pittsburgh Trial Will Test Weekly Semaglutide in Up to 1,200 Adults With Alcohol or Opioid Use Disorder
The Center for Addiction Science, Policy and Research (CASPR) and Pennsylvania's Allegheny County Department of Human Services plan a randomized trial, expected to start in early 2027, in which half of up to 1,200 adults with alcohol use disorder, opioid use disorder, or both will receive weekly semaglutide for 52 weeks on top of standard addiction treatment, The Pharmacist reported on November 10. Researchers will use county records to track rearrest, housing, employment, and health care costs; UPMC Western Psychiatric Hospital will be the lead clinical site.